Tamoxifen is one of the most frequently prescribed drugs in the treatment of ER + breast cancer among younger women because it can be prescribed at any age or menopausal status, while aromatase inhibitors are recommended for use with post-menopausal women (Palmer et al., 2008). This evidence concerns the gene CYP19A1 and breast cancer.